In a preclinical study, the reduction of ABCB1 and BCL-2 proteins via codelivery of siABCB1 and siBCL2, respectively, sensitized paclitaxel- and cisplatin-resistant SKOV3 and A2780 ovarian cancer cells to therapeutics [223]. This evidence concerns the gene BCL2 and ovarian carcinoma.